Amcad Biomed (ROCO:4188) Cyclically Adjusted Book per Share: NT$11.44 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
53 GF Score
Price NT$9.45
GF Value NT$9.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Amcad Biomed Cyclically Adjusted Book per Share?

Amcad Biomed ROCO:4188 -0.32% 53 Cyclically Adjusted Book per Share is NT$11.44 as of Dec. 2025. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Amcad Biomed's adjusted book value per share for the three months ended in Dec. 2025 was NT$8.233. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$11.44 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Amcad Biomed's average Cyclically Adjusted Book Growth Rate was -1.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Amcad Biomed was 1.30% per year. The lowest was 1.30% per year. And the median was 1.30% per year.

As of today (2026-08-01), Amcad Biomed's current stock price is NT$9.45. Amcad Biomed's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$11.44. Amcad Biomed's Cyclically Adjusted PB Ratio of today is 0.83.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Amcad Biomed was 2.99. The lowest was 0.87. And the median was 1.46.


Amcad Biomed  (ROCO:4188) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Amcad Biomed's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.45/11.44
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Amcad Biomed was 2.99. The lowest was 0.87. And the median was 1.46.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Amcad Biomed Cyclically Adjusted Book per Share Related Terms


Amcad Biomed Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Amcad Biomed's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amcad Biomed Cyclically Adjusted Book per Share Chart

Amcad Biomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 11.01 11.42 11.55 11.44

Amcad Biomed Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.55 11.59 11.58 11.56 11.44

ROCO:4188 vs ABT, SYK, MDT: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, Amcad Biomed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Cyclically Adjusted PB Ratio falls into.


ROCO:4188
53GF Score
Amcad Biomed Corp ROCO:4188
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amcad Biomed Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amcad Biomed's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=8.233/324.0540*324.0540
=8.233

Current CPI (Dec. 2025) = 324.0540.

Amcad Biomed Quarterly Data

Book Value per Share CPI Adj_Book
201603 8.348 238.132 11.360
201606 13.018 241.018 17.503
201609 12.801 241.428 17.182
201612 12.577 241.432 16.881
201703 12.305 243.801 16.355
201706 12.041 244.955 15.929
201709 11.809 246.819 15.504
201712 11.500 246.524 15.117
201803 11.546 249.554 14.993
201806 11.323 251.989 14.561
201809 10.977 252.439 14.091
201812 10.605 251.233 13.679
201903 10.459 254.202 13.333
201906 10.361 256.143 13.108
201909 10.094 256.759 12.740
201912 9.842 256.974 12.411
202003 9.323 258.115 11.705
202006 9.362 257.797 11.768
202009 9.252 260.280 11.519
202012 9.150 260.474 11.383
202103 9.028 264.877 11.045
202106 9.000 271.696 10.734
202109 8.959 274.310 10.584
202112 8.879 278.802 10.320
202203 8.758 287.504 9.871
202206 8.613 296.311 9.419
202209 8.259 296.808 9.017
202212 7.804 296.797 8.521
202303 7.645 301.836 8.208
202306 7.407 305.109 7.867
202309 7.200 307.789 7.580
202312 6.991 306.746 7.385
202403 6.697 312.332 6.948
202406 6.566 314.175 6.772
202409 9.084 315.301 9.336
202412 8.979 315.605 9.219
202503 8.654 319.799 8.769
202506 8.402 322.561 8.441
202509 8.291 324.800 8.272
202512 8.233 324.054 8.233

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$11.44 mean?
Amcad Biomed (ROCO:4188) has a Cyclically Adjusted Book per Share of NT$11.44 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Amcad Biomed and its competitors.
Is Amcad Biomed's Cyclically Adjusted Book per Share too high?
Amcad Biomed's current Cyclically Adjusted Book per Share is NT$11.44. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Cyclically Adjusted Book per Share compare to ABT and SYK?
Amcad Biomed's Cyclically Adjusted Book per Share of NT$11.44 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Amcad Biomed and its competitors. Amcad Biomed's current Cyclically Adjusted Book per Share is NT$11.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is NT$11.44. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Cyclically Adjusted Book per Share is NT$11.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10. GuruFocus considers Amcad Biomed to be Fairly Valued.

Key valuation signals for ROCO:4188:

  • Cyclically Adjusted Book per Share: NT$11.44
  • GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score

Get the complete analysis for ROCO:4188

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$9.45
Price
NT$9.10
GF Value